Literature DB >> 26481149

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.

Paulus Kirchhof1, Günter Breithardt2, Jeroen Bax3, Gerlinde Benninger4, Carina Blomstrom-Lundqvist5, Giuseppe Boriani6, Axel Brandes7, Helen Brown8, Martina Brueckmann9, Hugh Calkins10, Melanie Calvert11, Vincent Christoffels12, Harry Crijns13, Dobromir Dobrev14, Patrick Ellinor15, Larissa Fabritz16, Thomas Fetsch17, S Ben Freedman18, Andrea Gerth19, Andreas Goette20, Eduard Guasch21, Guido Hack22, Laurent Haegeli23, Stephane Hatem24, Karl Georg Haeusler25, Hein Heidbüchel26, Jutta Heinrich-Nols27, Francoise Hidden-Lucet28, Gerd Hindricks29, Steen Juul-Möller30, Stefan Kääb31, Lukas Kappenberger32, Stefanie Kespohl33, Dipak Kotecha11, Deirdre A Lane11, Angelika Leute4, Thorsten Lewalter34, Ralf Meyer35, Lluis Mont21, Felix Münzel36, Michael Nabauer19, Jens C Nielsen37, Michael Oeff38, Jonas Oldgren39, Ali Oto40, Jonathan P Piccini41, Art Pilmeyer42, Tatjana Potpara43, Ursula Ravens44, Holger Reinecke45, Thomas Rostock46, Joerg Rustige30, Irene Savelieva47, Renate Schnabel48, Ulrich Schotten49, Lars Schwichtenberg33, Moritz F Sinner50, Gerhard Steinbeck51, Monika Stoll52, Luigi Tavazzi53, Sakis Themistoclakis54, Hung Fat Tse55, Isabelle C Van Gelder56, Panagiotis E Vardas57, Timo Varpula58, Alphons Vincent35, David Werring59, Stephan Willems48, André Ziegler60, Gregory Y H Lip11, A John Camm47.   

Abstract

At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF), and many more suffer from undiagnosed, subclinical, or 'silent' AF. Atrial fibrillation-related cardiovascular mortality and morbidity, including cardiovascular deaths, heart failure, stroke, and hospitalizations, remain unacceptably high, even when evidence-based therapies such as anticoagulation and rate control are used. Furthermore, it is still necessary to define how best to prevent AF, largely due to a lack of clinical measures that would allow identification of treatable causes of AF in any given patient. Hence, there are important unmet clinical and research needs in the evaluation and management of AF patients. The ensuing needs and opportunities for improving the quality of AF care were discussed during the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference in Nice, France, on 22 and 23 January 2015. Here, we report the outcome of this conference, with a focus on (i) learning from our 'neighbours' to improve AF care, (ii) patient-centred approaches to AF management, (iii) structured care of AF patients, (iv) improving the quality of AF treatment, and (v) personalization of AF management. This report ends with a list of priorities for research in AF patients. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Antiarrhythmic drugs; Anticoagulation; Atrial fibrillation; Bleeding; Cardiovascular risk; Catheter ablation; Outcomes; Quality of care; Rate control; Research; Research priorities

Mesh:

Year:  2015        PMID: 26481149     DOI: 10.1093/europace/euv304

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  38 in total

Review 1.  [Implantable loop recorder in atrial fibrillation and after catheter ablation].

Authors:  K Fikenzer; N Dagres; G Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2016-11-10

2.  Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study.

Authors:  Marco Proietti; Alessandro Nobili; Valeria Raparelli; Laura Napoleone; Pier Mannuccio Mannucci; Gregory Y H Lip
Journal:  Clin Res Cardiol       Date:  2016-05-31       Impact factor: 5.460

3.  Advances in cardiac cellular electrophysiology - Relevance for clinical translation.

Authors:  Ursula Ravens; Andreas Goette
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-03

Review 4.  The burden of proof: The current state of atrial fibrillation prevention and treatment trials.

Authors:  Rosita Zakeri; David R Van Wagoner; Hugh Calkins; Tom Wong; Heather M Ross; E Kevin Heist; Timothy E Meyer; Peter R Kowey; Robert J Mentz; John G Cleland; Bertram Pitt; Faiez Zannad; Cecilia Linde
Journal:  Heart Rhythm       Date:  2017-02-02       Impact factor: 6.343

5.  Evaluating the cost-effectiveness of catheter ablation of atrial fibrillation.

Authors:  Chukwuemeka Daniel Iroegbu; Wangping Chen; Xun Wu; Luo Cheng; Hao Zhang; Ming Wu; Yuan Zhao; Li Ming Liu; Jinfu Yang
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

Review 6.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

7.  Inhibition of Small-Conductance Ca2+-Activated K+ Channels: The Long-Awaited Breakthrough for Antiarrhythmic Drug Therapy of Atrial Fibrillation?

Authors:  Jordi Heijman; Dobromir Dobrev
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-10

8.  Structured care of patients with atrial fibrillation improves guideline adherence.

Authors:  Neshro Barmano; Ulla Walfridsson; Håkan Walfridsson; Jan-Erik Karlsson
Journal:  J Atr Fibrillation       Date:  2016-12-31

9.  Variations in follow-up after atrial fibrillation ablation.

Authors:  Kathryn A Wood; Angel H Barnes
Journal:  J Am Assoc Nurse Pract       Date:  2020-05-06       Impact factor: 1.165

Review 10.  Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment.

Authors:  Larissa Fabritz; Eduard Guasch; Charalambos Antoniades; Isabel Bardinet; Gerlinde Benninger; Tim R Betts; Eva Brand; Günter Breithardt; Gabriela Bucklar-Suchankova; A John Camm; David Cartlidge; Barbara Casadei; Winnie W L Chua; Harry J G M Crijns; Jon Deeks; Stéphane Hatem; Françoise Hidden-Lucet; Stefan Kääb; Nikos Maniadakis; Stephan Martin; Lluis Mont; Holger Reinecke; Moritz F Sinner; Ulrich Schotten; Taunton Southwood; Monika Stoll; Panos Vardas; Reza Wakili; Andy West; André Ziegler; Paulus Kirchhof
Journal:  Nat Rev Cardiol       Date:  2015-12-24       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.